Development of ALS gene therapies for targeted protein degradation of TDP-43

Ended Project Grant Awarded Last action

Award ID
HT94252410575
Recipient
Awarding agency
Obligated
$749,995

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Australia

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

This $749,995 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of gene therapies for the targeted degradation of the TDP-43 protein to treat Amyotrophic Lateral Sclerosis (ALS) at Macquarie University in Australia. The project aims to advance therapeutic approaches for this neurodegenerative disease. Macquarie University, a non-profit educational institution, will conduct the research over a 2-year period from Sep 1, 2024 to Aug 31, 2026. The grant award represents Macquarie University's ongoing collaboration with U.S. federal agencies on innovative biomedical research across diverse domains, including previous contract work for the Department of Defense and grant funding from the National Institutes of Health.

Quick answers

Who received award HT94252410575?

HT94252410575 was awarded to Macquarie University by Defense Health Agency (Department of Defense) on September 1, 2024.

How much is award HT94252410575 worth?

$749,995 has been obligated on HT94252410575.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login